WST

WST Cost of Revenue

$2.10BTTM · USD

Period ending:

WST FY Cost of RevenueUSD
WST FY Cost of Revenue1985-12-31: $128.00M1986-12-31: $160.20M1987-12-31: $174.40M1988-12-31: $197.40M1989-12-31: $206.70M1990-12-31: $221.50M1991-12-31: $221.40M1992-12-31: $217.80M1993-12-31: $222.10M1994-12-31: $225.90M1995-12-31: $265.10M1996-12-31: $302.00M1997-12-31: $288.50M1998-12-31: $282.20M1999-12-31: $289.10M2000-12-31: $289.70M2001-12-31: $280.80M2002-12-31: $302.10M2003-12-31: $334.90M2004-12-31: $374.10M2005-12-31: $505.90M2006-12-31: $651.50M2007-12-31: $728.30M2008-12-31: $748.50M2009-12-31: $752.10M2010-12-31: $787.10M2011-12-31: $853.60M2012-12-31: $878.60M2013-12-31: $938.70M2014-12-31: $973.80M2015-12-31: $943.90M2016-12-31: $1.01B2017-12-31: $1.09B2018-12-31: $1.17B2019-12-31: $1.23B2020-12-31: $1.38B2021-12-31: $1.66B2022-12-31: $1.75B2023-12-31: $1.82B2024-12-31: $1.89B2025-12-31: $1.97B$1.97B$0.00
1985-12-312025-12-31

Source: Financial Modeling Prep (FMP). Annual fiscal periods; reported in USD. Dates are period ends; a fiscal year may differ from a calendar year.

WST cost of revenue history

Direct costs attributable to producing goods sold. The available annual fiscal periods series contains 41 observations from Dec 31, 1985 to Dec 31, 2025.

West Pharmaceutical Services Cost of Revenue — Annual fiscal periods (USD)
Period endingCost of Revenue (USD)
1,970,400,000
1,890,500,000
1,818,400,000
1,746,600,000
1,657,300,000
1,378,800,000
1,234,800,000
1,171,700,000
1,085,400,000
1,008,100,000
943,900,000
973,800,000
938,700,000
878,600,000
853,600,000
787,100,000
752,100,000
748,500,000
728,300,000
651,500,000
505,900,000
374,100,000
334,900,000
302,100,000
280,800,000
289,700,000
289,100,000
282,200,000
288,500,000
302,000,000
265,100,000
225,900,000
222,100,000
217,800,000
221,400,000
221,500,000
206,700,000
197,400,000
174,400,000
160,200,000
128,000,000

Compare cost of revenue

All WST financial metrics · WST stock overview · How to interpret financial metrics

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.